Physician profile
Laura Buck
NPI 1346524519
$19,809.01
in general payments reported to CMS, 2019-2025
45 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,887 · 2022: $8,329 · 2023: $3,509 · 2024: $838 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,221 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,221.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,372.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $6,728.50 | 2021-2025 | Valtoco |
| Ucb, INC. | $1,992.66 | 2021-2025 | Fintepla, Briviact |
| Abbvie INC. | $1,653.82 | 2021-2025 | |
| Livanova USA, INC. | $1,372.40 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $1,255.04 | 2021-2025 | Xcopri |
| Lundbeck LLC | $696.35 | 2021-2025 | Vyepti, Rexulti |
| Grifols USA, LLC | $521.27 | 2021-2025 | Gamunex-C |
| Biogen, INC. | $505.76 | 2021-2022 | |
| Pfizer INC. | $387.00 | 2025 | |
| Amgen INC. | $384.43 | 2021-2025 | Uplizna |
| Eisai INC. | $363.02 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $329.25 | 2022-2024 | Ultomiris |
| Boston Scientific Corporation | $285.92 | 2023 | Watchman Access System, Watchman Flx |
| Sunovion Pharmaceuticals INC. | $278.50 | 2021-2022 | |
| Celgene Corporation | $277.84 | 2023 | Zeposia |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.